Safety and antibody response to inactivated COVID‐19 vaccine in patients with chronic hepatitis B virus infection. (28th February 2022)

• Record Type: Journal Article
• Authors: He, Taiyu; Zhou, Yingzhi; Xu, Pan; Ling, Ning; Chen, Min; Huang, Tianquan; Zhang, Biqiong; Yang, Ziqiao; Ao, Ling; Li, Hu; Chen, Zhiwei; Zhang, Dazhi; Shi, Xiaofeng; Lei, Yu; Wang, Zhiyi; Zeng, Weiqun; Hu, Peng; Lan, Yinghua; Zhou, Zhi; Kang, Juan; Huang, Ying; Shi, Tongdong; Pan, Qingbo; Zhu, Qian; Ran, Xiping; Zhang, Yingzhi; Song, Rui; Xiang, Dejuan; Xiao, Shuang; Zhang, Gaoli; Shen, Wei; Peng, Mingli; Cai, Dachuan; Ren, Hong;
• Is Part Of: Liver international. Volume 42:Number 6(2022)
• Page Start: 1287
• Page End: 1296
• Publication Date: 2022-02-28
• Subjects: antibody response -- CHB -- cirrhosis -- COVID‐19 vaccine -- safety; Liver -- Periodicals; Liver -- Diseases -- Periodicals; 616.362
• DOI: 10.1111/liv.15173
• Languages: English
• ISSNs: 1478-3223

Abstract

Abstract: Background and Aims: The safety and antibody responses of coronavirus disease 2019 (COVID‐19) vaccination in patients with chronic hepatitis B (CHB) virus infection is still unclear, and exploration in safety and antibody responses of COVID‐19 vaccination in CHB patients is significant in clinical practice. Methods: 362 adult CHB patients and 87 healthy controls at an interval of at least 21 days after a full‐course vaccination (21–105 days) were enrolled. Adverse events (AEs) were collected by questionnaire. The antibody profiles at 1, 2 and 3 months were elucidated by determination of anti‐spike IgG, anti‐receptor‐binding domain (RBD) IgG, and RBD‐angiotensin‐converting enzyme 2 blocking antibody. SARS‐CoV‐2 specific B cells were also analysed. Results: All AEs were mild and self‐limiting, and the incidence was similar between CHB patients and controls. Seropositivity rates of three antibodies were similar between CHB patients and healthy controls at 1, 2 and 3 months, but CHB patients had lower titers of three antibodies at 1 month. Compared to healthy controls, HBeAg‐positive CHB patients had higher titers of three antibodies at 3 months (all P < .05) and a slower decline in antibody titers. Frequency of RBD‐specific B cells was positively correlated with titers of anti‐RBD IgG (OR = 1.067, P = .004), while liver cirrhosis, antiviral treatment, levels of HBV DNA, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and total bilirubin (TB) were not correlated with titers of anti‐RBD IgG. Conclusions: Inactivated COVID‐19 vaccines were well tolerated, and induced effective antibody response against SARS‐CoV‐2 in CHB patients.